Showing results (121-130 of 366) with videos related to

Sort By:
Pageof 37
Lung Cancer (Amsterdam, Netherlands)|November 21, 2022
Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancerJulien Mazieres, Laura Iadeluca, Alice T Shaw, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 3, 2019
Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP)Rafal Dziadziuszko, Egbert F Smit, Urania Dafni, et al.
Future Oncology (London, England)|September 29, 2021
Plain language summary of the CROWN study comparing lorlatinib with crizotinib for people with untreated non-small cell lung cancerBenjamin J Solomon, Todd M Bauer, Filippo de Marinis, et al.
Therapeutic Advances in Medical Oncology|April 7, 2023
A transcriptomics approach to expand therapeutic options and optimize clinical trials in oncologyVladimir Lazar, Baolin Zhang, Shai Magidi, et al.
Journal for Immunotherapy of Cancer|August 4, 2025
Atezolizumab and bevacizumab, with or without radiotherapy, versus docetaxel in patients with metastatic non-small cell lung cancer previously treated with a checkpoint inhibitor and chemotherapy: results from the randomized, phase Ib/II MORPHEUS-Lung studyFrancois Ghiringhelli, Yaacov R Lawrence, Enriqueta Felip, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 24, 2025
Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine CarcinomasMartin Wermke, Valentina Gambardella, Yasutoshi Kuboki, et al.
BMC Cancer|October 25, 2024
Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLCArmando Santoro, Garrido Pilar, Daniel S W Tan, et al.
Frontiers in Medicine|September 8, 2022
Incidence and characteristics of adverse drug reactions in a cohort of patients treated with PD-1/PD-L1 inhibitors in real-world practiceMònica Sabaté Gallego, Eulàlia Pérez Esquirol, Núria Garcia Doladé, et al.
Lung Cancer (Amsterdam, Netherlands)|May 29, 2026
Efficacy and safety of subcutaneous and intravenous administration of atezolizumab in patients with non-small cell lung cancer, including early-stage, locally advanced or metastatic disease: Updated results of the IMscin001 and IMscin002 randomized studiesMauricio Burotto, Zanete Zvirbule, Renzo Alvarez, et al.
Lung Cancer (Amsterdam, Netherlands)|August 27, 2019
Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studiesKaname Nosaki, Hideo Saka, Yukio Hosomi, et al.
Pageof 37